Compazine (Prochlorperazine): A Comprehensive Overview > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Compazine, the brand name for prochlorperazine, is a phenothiazine antipsychotic medication primarily used to treat nausea and vomiting, as well as certain psychiatric disorders. First approved by the U.S. Food and Drug Administration (FDA) in the 1950s, it remains a well-established drug in clinical practice due to its efficacy and safety profile when used appropriately. This report provides an in-depth review of Compazine, covering its pharmacology, therapeutic uses, dosing, adverse effects, contraindications, and clinical considerations.

Pharmacology and Mechanism of Action
Prochlorperazine belongs to the phenothiazine class, which acts primarily as a dopamine D2 receptor antagonist in the central nervous system. By blocking dopamine receptors in the chemoreceptor trigger zone (CTZ) of the medulla oblongata, it effectively suppresses nausea and vomiting. Additionally, its antipsychotic effects arise from blockade of dopamine receptors in the mesolimbic and mesocortical pathways. The drug also exhibits anticholinergic, antihistaminic, and weak alpha-adrenergic blocking properties, which contribute to both its therapeutic and adverse effects. Prochlorperazine is metabolized by the liver via several cytochrome P450 isoenzymes, including CYP2D6, and can interact with other drugs sharing these pathways.

Therapeutic Uses

1. Nausea and Vomiting: Compazine is most commonly prescribed for the management of severe nausea and vomiting of various etiologies, including postoperative nausea, chemotherapy-induced emesis, and gastroenteritis. It is considered a first-choice antiemetic in many clinical settings, particularly when other agents like ondansetron are contraindicated or unavailable.
   
2. Psychiatric Disorders: For schizophrenia and other psychotic disorders, prochlorperazine is used as a second-line therapy, typically when first-generation antipsychotics are indicated. Its efficacy in reducing positive symptoms (hallucinations, delusions) is well documented, though it is less favored due to extrapyramidal side effects compared to newer atypical antipsychotics.
   
3. Vertigo and Migraine: Off-label use includes treatment of vestibular vertigo and migraine-associated nausea; however, evidence is limited and it is not a standard recommendation.
   
4. Intractable Hiccups: Rarely, prochlorperazine is used for severe, persistent hiccups, based on its central dopamine-blocking action.
   
   

Compazine is available in multiple formulations: oral tablets (5 mg and 10 mg), extended-release capsules (10 mg and 15 mg), injectable solution (5 mg/mL), and rectal suppositories (2.5 mg, 5 mg, and 25 mg). For nausea and vomiting: oral typical doses range from 5 to 10 mg every 6 to 8 hours, with a maximum of 40 mg per day. The extended-release form is taken once or twice daily. For psychosis: higher doses are used, up to 150 mg per day in divided doses. The injectable route is reserved for acute agitation or severe nausea. Dosing adjustments are necessary in elderly patients and those with hepatic or renal impairment due to altered clearance.

Adverse Effects and Safety Profile
Compazine has a well-characterized adverse effect profile, largely dose-dependent. The most common are extrapyramidal symptoms (EPS) such as dystonia (acute muscle spasms, often in the neck and eyes), akathisia (restlessness), parkinsonism (tremor, rigidity), and tardive dyskinesia (irreversible involuntary movements) with long-term use. These effects are especially prominent in children, the elderly, and those with preexisting neurological disorders. Anticholinergic effects include dry mouth, blurred vision, constipation, and urinary retention. Antihistaminic effects cause sedation and weight gain. Cardiovascular effects: orthostatic hypotension, tachycardia, and QT interval prolongation (risk of torsades de pointes) – caution is advised in patients with cardiac disease or electrolyte imbalances. Neuroleptic malignant syndrome (NMS) is a rare but life-threatening syndrome characterized by hyperthermia, rigidity, autonomic instability, and altered mental status. Hepatic effects: cholestatic jaundice has been reported, especially early in treatment. Endocrine: hyperprolactinemia leading to galactorrhea, gynecomastia, menstrual irregularities, and sexual dysfunction. Skin: photosensitivity and rash; pigmentation changes with chronic use.

Contraindications and Precautions
Compazine is contraindicated in patients with known hypersensitivity to phenothiazines, in comatose states, severe central nervous system depression, and in pediatric patients less than 2 years of age or those weighing less than 9 kg. Cautious use is warranted in individuals with epilepsy (lowers seizure threshold), hepatic or renal disease, Parkinson’s disease, narrow-angle glaucoma, prostatic hypertrophy, and hematologic disorders. It should be avoided in combination with other drugs that prolong the QT interval, such as certain antibiotics and antiarrhythmics. Because of its anticholinergic effects, it may worsen conditions like myasthenia gravis. In pregnancy, prochlorperazine is category C; limited data suggest possible risk, so it is used only when the benefit outweighs potential harm. It is excreted in breast milk, so breastfeeding is generally not recommended during therapy.

Clinical Considerations and Monitoring
Before initiating Compazine, baseline ECG, electrolyte levels, and liver function tests are recommended, especially in at-risk patients. During long-term therapy, periodic monitoring for extrapyramidal symptoms, tardive dyskinesia, and ophthalmologic changes (corneal deposits) should be performed. Gradual dose escalation minimizes sedation and orthostatic hypotension. Abrupt discontinuation may cause withdrawal symptoms or rebound psychosis. For acute dystonia, treatment with anticholinergic agents such as benztropine or diphenhydramine is effective. Tolerance to the sedative and antiemetic effects may develop over time. Drug interactions are numerous; concomitant use with other central nervous system depressants (alcohol, benzodiazepines, opioids) increases sedation. Prochlorperazine also reduces the efficacy of levodopa by blocking dopamine receptors.

Comparison with Other Antiemetics and Antipsychotics
Compared to newer antiemetics like ondansetron (a 5-HT3 antagonist), Compazine is older, has a broader side effect profile, but is less expensive. It is still preferred in cases where serotonin antagonists are not tolerated or are contraindicated. As an antipsychotic, prochlorperazine is less potent and more sedating than haloperidol, and carries a higher risk of EPS than most atypical antipsychotics. It is rarely used as a first-line antipsychotic today, but remains a valuable option in resource-limited settings or when patients have responded well to it historically.

Conclusion
Compazine (prochlorperazine) is a versatile and effective medication for the management of nausea and vomiting, and Abana 60pills à €49.64